Literature DB >> 26659569

Ebola vaccine R&D: Filling the knowledge gaps.

Donata Medaglini1, Ali M Harandi2, Tom H M Ottenhoff3, Claire-Anne Siegrist4.   

Abstract

With an emphasis on systems analyses, the VSV-EBOVAC project harnesses state-of-the-art technologies that illuminate mechanisms behind the observed immunogenicity and reactogenicity of the rVSV-ZEBOV vaccine and ensures that such information is shared among stakeholders.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26659569      PMCID： PMC6858855          DOI： 10.1126/scitranslmed.aad3106

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  18 in total

1.  Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.

Authors:  Michael Garbutt; Ryan Liebscher; Victoria Wahl-Jensen; Steven Jones; Peggy Möller; Ralf Wagner; Viktor Volchkov; Hans-Dieter Klenk; Heinz Feldmann; Ute Ströher
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  ADITEC: joining forces for next-generation vaccines.

Authors:  Rino Rappuoli; Donata Medaglini
Journal:  Sci Transl Med       Date:  2012-04-04       Impact factor: 17.956

3.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Authors:  Selidji T Agnandji; Angela Huttner; Madeleine E Zinser; Patricia Njuguna; Christine Dahlke; José F Fernandes; Sabine Yerly; Julie-Anne Dayer; Verena Kraehling; Rahel Kasonta; Akim A Adegnika; Marcus Altfeld; Floriane Auderset; Emmanuel B Bache; Nadine Biedenkopf; Saskia Borregaard; Jessica S Brosnahan; Rebekah Burrow; Christophe Combescure; Jules Desmeules; Markus Eickmann; Sarah K Fehling; Axel Finckh; Ana Rita Goncalves; Martin P Grobusch; Jay Hooper; Alen Jambrecina; Anita L Kabwende; Gürkan Kaya; Domtila Kimani; Bertrand Lell; Barbara Lemaître; Ansgar W Lohse; Marguerite Massinga-Loembe; Alain Matthey; Benjamin Mordmüller; Anne Nolting; Caroline Ogwang; Michael Ramharter; Jonas Schmidt-Chanasit; Stefan Schmiedel; Peter Silvera; Felix R Stahl; Henry M Staines; Thomas Strecker; Hans C Stubbe; Benjamin Tsofa; Sherif Zaki; Patricia Fast; Vasee Moorthy; Laurent Kaiser; Sanjeev Krishna; Stephan Becker; Marie-Paule Kieny; Philip Bejon; Peter G Kremsner; Marylyn M Addo; Claire-Anne Siegrist
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

4.  Big science for vaccine development.

Authors:  Rino Rappuoli; Donata Medaglini
Journal:  Vaccine       Date:  2014-06-25       Impact factor: 3.641

5.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Authors:  Daphne A Stanley; Anna N Honko; Clement Asiedu; John C Trefry; Annie W Lau-Kilby; Joshua C Johnson; Lisa Hensley; Virginia Ammendola; Adele Abbate; Fabiana Grazioli; Kathryn E Foulds; Cheng Cheng; Lingshu Wang; Mitzi M Donaldson; Stefano Colloca; Antonella Folgori; Mario Roederer; Gary J Nabel; John Mascola; Alfredo Nicosia; Riccardo Cortese; Richard A Koup; Nancy J Sullivan
Journal:  Nat Med       Date:  2014-09-07       Impact factor: 53.440

6.  Human Ebola virus infection results in substantial immune activation.

Authors:  Anita K McElroy; Rama S Akondy; Carl W Davis; Ali H Ellebedy; Aneesh K Mehta; Colleen S Kraft; G Marshall Lyon; Bruce S Ribner; Jay Varkey; John Sidney; Alessandro Sette; Shelley Campbell; Ute Ströher; Inger Damon; Stuart T Nichol; Christina F Spiropoulou; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

7.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

8.  A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making.

Authors:  Maria D Van Kerkhove; Ana I Bento; Harriet L Mills; Neil M Ferguson; Christl A Donnelly
Journal:  Sci Data       Date:  2015-05-26       Impact factor: 6.444

9.  Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak.

Authors:  T Yan; J Mu; E Qin; Y Wang; L Liu; D Wu; H Jia; Z Li; T Guo; X Wang; Y Qin; Y Li; S Chen; Y Zhang; J Zhang; Y Wu; S Wang; J Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-30       Impact factor: 5.103

10.  Ebola viral disease outbreak--West Africa, 2014.

Authors:  Meredith G Dixon; Ilana J Schafer
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-06-27       Impact factor: 17.586
View more
  8 in total

1.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 2.  Ebola virus disease candidate vaccines under evaluation in clinical trials.

Authors:  Karen A Martins; Peter B Jahrling; Sina Bavari; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2016-05-27       Impact factor: 5.217

3.  Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.

Authors:  James Duehr; Teddy John Wohlbold; Lisa Oestereich; Veronika Chromikova; Fatima Amanat; Madhusudan Rajendran; Sergio Gomez-Medina; Ignacio Mena; Benjamin R tenOever; Adolfo García-Sastre; Christopher F Basler; Cesar Munoz-Fontela; Florian Krammer
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

4.  The Propagation, Quantification, and Storage of Vesicular Stomatitis Virus.

Authors:  Alaa A Abdelmageed; Maureen C Ferran
Journal:  Curr Protoc Microbiol       Date:  2020-09

5.  A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

Authors:  Angela Huttner; Christophe Combescure; Stéphane Grillet; Mariëlle C Haks; Edwin Quinten; Christine Modoux; Selidji Todagbe Agnandji; Jessica Brosnahan; Julie-Anne Dayer; Ali M Harandi; Laurent Kaiser; Donata Medaglini; Tom Monath; Pascale Roux-Lombard; Peter G Kremsner; Tom H M Ottenhoff; Claire-Anne Siegrist
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

Review 6.  Development of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon.

Authors:  Michael Ramharter; Selidji T Agnandji; Ayôla A Adegnika; Bertrand Lell; Ghyslain Mombo-Ngoma; Martin P Grobusch; Matthew McCall; Riko Muranaka; Andrea Kreidenweiss; Thirumalaisamy P Velavan; Meral Esen; Frieder Schaumburg; Abraham Alabi; Christiane Druml; Benjamin Mordmüller; Carsten Köhler; Peter G Kremsner
Journal:  Wien Klin Wochenschr       Date:  2021-01-04       Impact factor: 1.704

7.  Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.

Authors:  Selidji T Agnandji; José F Fernandes; Emmanuel B Bache; Régis M Obiang Mba; Jessica S Brosnahan; Lumeka Kabwende; Paul Pitzinger; Pieter Staarink; Marguerite Massinga-Loembe; Verena Krähling; Nadine Biedenkopf; Sarah Katharina Fehling; Thomas Strecker; David J Clark; Henry M Staines; Jay W Hooper; Peter Silvera; Vasee Moorthy; Marie-Paule Kieny; Akim A Adegnika; Martin P Grobusch; Stephan Becker; Michael Ramharter; Benjamin Mordmüller; Bertrand Lell; Sanjeev Krishna; Peter G Kremsner
Journal:  PLoS Med       Date:  2017-10-06       Impact factor: 11.069

Review 8.  Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population.

Authors:  Annalisa Ciabattini; Paolo Garagnani; Francesco Santoro; Rino Rappuoli; Claudio Franceschi; Donata Medaglini
Journal:  Semin Immunopathol       Date:  2020-11-06       Impact factor: 9.623
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.